S8 Ep8: Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment
Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.
21m Dec 22, 2022
21m
S8 Ep7: Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.
23m Dec 19, 2022
23m
S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
13m Dec 15, 2022
13m
S8 Ep5: Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
Nicholas Acuna discusses research showing that incidence of liver cancer increases over time in people of Mexican descent living in Los Angeles, the “Latino paradox” in health outcomes, and the next steps for this research.
16m Dec 12, 2022
16m
S8 Ep4: Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL
Dr Brody previews mantle cell lymphoma data being presented at the 2022 ASH Annual Meeting and Exposition, including promising data on pirtobrutinib from the BRUIN trial, the potential for CAR T-cell therapy as evidenced in the ZUMA-2 trial, and how immunotherapies such as glofitamab are expanding the treatment paradigm.
13m Dec 08, 2022
13m
S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.
17m Dec 05, 2022
17m
S8 Ep2: Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer
Dr Leone discusses the distinguishing features of male breast cancer, the benefits and limitations of current treatments, and the importance of raising awareness about this breast cancer subset to propel further research.
15m Dec 01, 2022
15m
S8 Ep1: Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship
Dr Florez discusses why cancer care equity and survivorship should be a priority for all physicians, the steps the health care system needs to take to address disparities in these areas, and specific ways that Dana-Farber is working to close these gaps.
14m Nov 28, 2022
14m
S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.
19m Nov 24, 2022
19m
S7 Ep49: Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.
13m Nov 21, 2022
13m
S7 Ep48: Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.
22m Nov 17, 2022
22m
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.
14m Nov 14, 2022
14m
S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.
26m Nov 10, 2022
26m
S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.
22m Nov 07, 2022
22m
S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.
11m Nov 03, 2022
11m
S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents to treat solid tumors, and the challenges of investigating rare cancers.
22m Oct 31, 2022
22m
S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.
15m Oct 27, 2022
15m
S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
Dr Shah discusses the FDA approval of sodium thiosulfate in pediatric patients with solid tumors treated with cisplatin, key efficacy and safety data from the SIOPEL6 and COG ACCL0431 trials, and the importance of multidisciplinary communication when prescribing and administering the agent.
16m Oct 24, 2022
16m
S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.
47m Oct 20, 2022
47m
S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.
15m Oct 17, 2022
15m
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and other solid tumors.
19m Oct 13, 2022
19m
S7 Ep37: Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Dr Brentjens discusses targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.
13m Oct 10, 2022
13m
S7 Ep36: Velcheti Discusses Mobile Telehealth-Based Research to Close Cancer Care Gaps
Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patient populations.
11m Oct 06, 2022
11m
S7 Ep35: FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer
Dr Oh discusses the FDA approval of durvalumab plus gemcitabine and cisplatin in biliary tract cancer, the tolerability of the regimen, and the importance of using immunotherapy to treat this disease.
9m Oct 03, 2022
9m
S7 Ep34: Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors
Dr Shepard discusses the unpredictable course of desmoid tumors, the use of TKIs for these tumors, and findings from 2 trials presented at the 2022 ESMO Congress that may represent new treatment options for patients with desmoid tumors.
20m Sep 29, 2022
20m
S7 Ep33: Deol on the Importance of a Well-Rounded Fellowship Experience
Dr Deol discusses what he wants his trainees to take from the fellowship program he directs, how his colleagues help fellows find jobs, and how he helps fellows deal with grief.
18m Sep 26, 2022
18m
S7 Ep32: Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.
16m Sep 22, 2022
16m
S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigatinib, and the importance of identifying chromosomal abnormalities in patients with this aggressive disease.
10m Sep 19, 2022
10m
S7 Ep30: Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underlying cancers, and how amifampridine can help manage this disease by improving motor and autonomic symptoms.
14m Sep 15, 2022
14m
S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC
Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.
11m Sep 12, 2022
11m
S7 Ep28: Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in cutaneous T-cell lymphoma.
19m Sep 08, 2022
19m
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety data from the DESTINY-Breast04 trial, and how these findings pave the way for further progress across cancer therapy.
12m Sep 05, 2022
12m
S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers
Drs Iams and Shah discuss the process of diagnosing Lambert-Eaton myasthenic syndrome in neuroendocrine cancers, how the condition affects patient prognoses, and the primary goals of delivering coordinated care with in combination with cancer treatments.
20m Sep 01, 2022
20m
S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating the novel ULK inhibitor DCC-3116 in patients with advanced or metastatic RAS or RAF–mutated solid tumors, and how vimiseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
25m Aug 29, 2022
25m
S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the DESTINY-Lung02 trial, and the optimal use of companion diagnostic tests in the field.
11m Aug 25, 2022
11m
S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.
12m Aug 22, 2022
12m
S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these differences, and ways these disparities can be addressed.
20m Aug 18, 2022
20m
S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.
14m Aug 15, 2022
14m
S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
17m Aug 11, 2022
17m
S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to continue to work toward progress in the field even when treatment outcomes were dismal. They also share their experiences with being women in their chosen career paths, such as how their gender has influenced their professional and personal decis...
1hr 2m Aug 08, 2022
1hr 2m
S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment decisions, and the need for honest and comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.
16m Aug 04, 2022
16m
S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
Dr Subbiah discusses findings from 4 presentations that stood out to him from the 2022 ASCO Annual Meeting: phase 2 data (NCT04165772) demonstrating a 100% complete response rate in 12 patients with mismatch repair–deficient, locally advanced rectal cancer who received dostarlimab (Jemperli); DESTINY-Breast04 (NCT03734029), results he called “important and practice changing” for patients with H...
12m Aug 01, 2022
12m
S7 Ep18: FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.
20m Jul 28, 2022
20m
S7 Ep17: Wagner Weighs In On Research and Development in Angiosarcoma
Dr Wagner talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward, and the potential for immunotherapy in this disease.
25m Jul 25, 2022
25m
S7 Ep16: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with BRAF V600E–mutant metastatic or unresectable solid tumors and contextualizes the pivotal data for rare tumor types.
14m Jul 21, 2022
14m
S7 Ep15: Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.
8m Jul 18, 2022
8m
S7 Ep14: Jain Discusses the Driving Forces of Gender Inequities in Medicine
Dr Jain discusses an article she authored, titled “We’re Running Up the Wrong Side of the Escalator,” which confronts systemic and structural obstacles facing women in medicine.
31m Jul 14, 2022
31m
S7 Ep13: Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer
Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.
18m Jul 11, 2022
18m
S7 Ep12: Research Reflections: Tarantino Talks Through the Implications of ASCO 2022 Data in Breast Cancer
Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer treatment paradigm going forward.
23m Jul 07, 2022
23m
S7 Ep11: Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)
Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.
24m Jul 04, 2022
24m